Compare Stocks → Your Money is Not Safe (From American Alternative) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:CYCCNASDAQ:HILSNASDAQ:TRVN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$2.17-6.5%$1.61$0.76▼$14.00$8.79M1.485.35 million shs153,407 shsCYCCCyclacel Pharmaceuticals$1.85-5.6%$2.35$1.52▼$13.20$2.44M0.54133,567 shs37,739 shsHILSHillstream BioPharma$0.38+2.7%$0.39$0.19▼$2.65$4.06M3.081.39 million shs34,950 shsTRVNTrevena$0.37-9.9%$0.51$0.30▼$3.28$6.71M1.1180,397 shs1.23 million shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals-6.47%-27.18%+31.52%+64.39%-71.05%CYCCCyclacel Pharmaceuticals-5.13%-4.64%-21.28%-12.32%-81.86%HILSHillstream BioPharma+2.72%-8.52%-5.55%-2.88%-58.94%TRVNTrevena-8.09%-11.38%-33.45%-46.88%-49.52%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.2732 of 5 stars3.35.00.00.00.00.00.6HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ATRVNTrevena1.0673 of 5 stars3.53.00.00.00.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.001,035.14% UpsideHILSHillstream BioPharma2.00HoldN/AN/ATRVNTrevena3.00Buy$9.002,359.02% UpsideCurrent Analyst RatingsLatest CYCC, ADIL, HILS, and TRVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/ACYCCCyclacel Pharmaceuticals$420K5.81N/AN/A$0.57 per share3.25HILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ATRVNTrevena$3.12M2.15N/AN/A($0.44) per share-0.83Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)HILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ATRVNTrevena-$40.29M-$3.13N/AN/AN/AN/A-1,018.15%-98.93%5/20/2024 (Estimated)Latest CYCC, ADIL, HILS, and TRVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2024Q4 2023CYCCCyclacel Pharmaceuticals-$6.35-$6.23+$0.12-$6.23N/A$0.03 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90CYCCCyclacel PharmaceuticalsN/A0.910.91HILSHillstream BioPharmaN/A3.013.01TRVNTrevena8.354.664.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%CYCCCyclacel Pharmaceuticals23.58%HILSHillstream BioPharma13.36%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%CYCCCyclacel Pharmaceuticals8.47%HILSHillstream BioPharma30.24%TRVNTrevena2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals164.05 million3.47 millionNo DataCYCCCyclacel Pharmaceuticals2,0181.32 million1.21 millionOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableTRVNTrevena2318.32 million17.88 millionOptionableCYCC, ADIL, HILS, and TRVN HeadlinesSourceHeadlineTrevena gets grant for pharmaceutical composition for modulating S1P1 receptor activitypharmaceutical-technology.com - April 18 at 8:34 AMTrevena (TRVN) Price Target Decreased by 7.69% to 6.12msn.com - April 18 at 3:33 AMTrevena (NASDAQ:TRVN) Now Covered by StockNews.comamericanbankingnews.com - April 14 at 2:16 AMTrevena Inc TRVNmorningstar.com - April 5 at 11:56 PMDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In Bulgariamsn.com - April 4 at 2:44 AMTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environmentmsn.com - April 3 at 3:48 AMRecap: Trevena Q4 Earningsbenzinga.com - April 2 at 2:41 AMTrevena Reports Fourth Quarter 2023 Results and Provides Corporate Updateglobenewswire.com - April 1 at 7:00 AMTrevena gets grant for pharmaceutical process for preparing compound of formula (i)pharmaceutical-technology.com - March 28 at 10:37 AMTrevena files patent for treatment of acute respiratory distress syndrome using specific peptidespharmaceutical-technology.com - March 22 at 9:37 PMTrevena Cross cafe reopening as the Palm Tree Bistromsn.com - March 16 at 3:06 PMTrevena Cross Garden Centre, The Palm Tree Bistrofalmouthpacket.co.uk - March 14 at 1:26 PMThe Palm Tree Bistro at Trevena Cross Nurseries reopeningmsn.com - March 8 at 10:03 AMTrevena Stock (NASDAQ:TRVN), Short Interest Reportbenzinga.com - February 22 at 1:18 PMTrevena files to sell 2.78M shares for holdersmsn.com - January 10 at 7:29 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 8:45 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 3:44 PMTrevena announces private placement and warrant exercisemsn.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisemarkets.businessinsider.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 27 at 1:16 PMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’msn.com - December 16 at 1:50 AMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'msn.com - December 15 at 8:50 PMTrevena Awarded OLINVYK Agreement with Premier, Inc.finance.yahoo.com - December 4 at 8:26 AMTrevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meetingfinance.yahoo.com - December 4 at 8:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideeBay Steadily Climbs as Collectors Drive Growth March 25, 2024 6:29 AMView eBay Steadily Climbs as Collectors Drive Growth All Headlines Company DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Cyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Hillstream BioPharmaNASDAQ:HILSHillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.